Return to Listing

17 result(s) for Prostate

PI Name Protocol # Title
Tomasz Beer IRB00009204 Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Joshi Alumkal IRB00009259 Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Julie Graff IRB00009892 VAPORHCS/OHSU J: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Xin Li IRB00010345 Contrast Enhanced MRI of the Prostate
Julie Graff IRB00011025 Addition of Pembrolizumab Upon Progression on Enzalutamide in men with mCRPC
Julie Graff IRB00011227 VAPORHCS/OHSU J: A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer
Arthur Hung IRB00011268 Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Arthur Hung STUDY00015290 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
Tomasz Beer STUDY00015561 A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone. Protocol 1280.8
Joshi Alumkal STUDY00015617 Phase 1 Safety and Tolerability Study of ZEN003694 as a Single Agent in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-001)
Kerri Winters STUDY00015921 INTense Exercise foR surVivAL among men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-MCRPC): A Multicenter, Randomized, Controlled, Phase III Study
Raymond Bergan STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
Joshi Alumkal STUDY00016149 A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer
Joshi Alumkal STUDY00016294 Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002)
Julie Graff STUDY00016446 A Safety and Pharmacokinetics Study of Niraparib plus androgen receptor-targeted therapy (apalutamide or abiraterone acetate and prednisone) in Men with Metastatic Castration-Resistant Prostate Cancer (protocol 64091742PCR1001)
Julie Graff STUDY00016539 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration Resistant Prostate Cancer and DNA - Repair Anomalies (protocol 64091742PCR2001)
Kerri Winters STUDY00016703 Movember TrueNTH Community of Wellness
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080